Global Graft vs. Host Disease (GvHD) Stem Cell Therapy Market 2026 by Company, Regions, Type and Application, Forecast to 2032

January 2026 | 84 pages | ID: GB6F16CCD091EN
GlobalInfoResearch

Abstracts

According to our (Global Info Research) latest study, the global Graft vs. Host Disease (GvHD) Stem Cell Therapy market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.

Graft-versus-host disease (GVHD) is a potentially serious complication of allogeneic stem cell transplantation and reduced-intensity allogeneic stem cell transplantation. In this treatment, a patient’s own damaged or diseased blood-forming stem cells are destroyed. Then they are replaced with healthy stem cells from a donor.

The Graft vs. Host Disease (GvHD) Stem Cell Therapy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation

Graft vs. Host Disease (GvHD) Stem Cell Therapy market is split by Type and by Application. For the period 2026-2032, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type,

• Acute Graft-versus-host Disease
• Chronic Graft-versus-host Disease

Market segment by Application

• Preclinical
• Clinical Phase 1,2

Market segment by players, this report covers

• Osiris Therapeutics
• Belumosudil
• UChicago Medicine
• Leukemia & Lymphoma Society
• Dana-Farber Cancer Institute
• Mesoblast
• Takeda

Market segment by regions, regional analysis covers

North America
Europe
Asia-Pacific (China, Japan, South Korea, Rest of Asia)
South America
Middle East & Africa

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope of Graft vs. Host Disease (GvHD) Stem Cell Therapy
1.2 Classification of Graft vs. Host Disease (GvHD) Stem Cell Therapy by Type
  1.2.1 Overview: Global Graft vs. Host Disease (GvHD) Stem Cell Therapy Market Size by Type: 2026 Versus 2032
  1.2.2 Global Graft vs. Host Disease (GvHD) Stem Cell Therapy Revenue Market Share by Type in 2032
  1.2.3 Acute Graft-versus-host Disease
  1.2.4 Chronic Graft-versus-host Disease
1.3 Global Graft vs. Host Disease (GvHD) Stem Cell Therapy Market by Application
  1.3.1 Overview: Global Graft vs. Host Disease (GvHD) Stem Cell Therapy Market Size by Application: 2026 Versus 2032
  1.3.2 Preclinical
  1.3.3 Clinical Phase 1,2
1.4 Global Graft vs. Host Disease (GvHD) Stem Cell Therapy Market Size & Forecast
1.5 Market Drivers, Restraints and Trends
  1.5.1 Graft vs. Host Disease (GvHD) Stem Cell Therapy Market Drivers
  1.5.2 Graft vs. Host Disease (GvHD) Stem Cell Therapy Market Restraints
  1.5.3 Graft vs. Host Disease (GvHD) Stem Cell Therapy Trends Analysis

2 COMPANY PROFILES

2.1 Osiris Therapeutics
  2.1.1 Osiris Therapeutics Details
  2.1.2 Osiris Therapeutics Major Business
  2.1.3 Osiris Therapeutics Graft vs. Host Disease (GvHD) Stem Cell Therapy Product and Solutions
  2.1.4 Osiris Therapeutics Recent Developments and Future Plans
2.2 Belumosudil
  2.2.1 Belumosudil Details
  2.2.2 Belumosudil Major Business
  2.2.3 Belumosudil Graft vs. Host Disease (GvHD) Stem Cell Therapy Product and Solutions
  2.2.4 Belumosudil Recent Developments and Future Plans
2.3 UChicago Medicine
  2.3.1 UChicago Medicine Details
  2.3.2 UChicago Medicine Major Business
  2.3.3 UChicago Medicine Graft vs. Host Disease (GvHD) Stem Cell Therapy Product and Solutions
  2.3.4 UChicago Medicine Recent Developments and Future Plans
2.4 Leukemia & Lymphoma Society
  2.4.1 Leukemia & Lymphoma Society Details
  2.4.2 Leukemia & Lymphoma Society Major Business
  2.4.3 Leukemia & Lymphoma Society Graft vs. Host Disease (GvHD) Stem Cell Therapy Product and Solutions
  2.4.4 Leukemia & Lymphoma Society Recent Developments and Future Plans
2.5 Dana-Farber Cancer Institute
  2.5.1 Dana-Farber Cancer Institute Details
  2.5.2 Dana-Farber Cancer Institute Major Business
  2.5.3 Dana-Farber Cancer Institute Graft vs. Host Disease (GvHD) Stem Cell Therapy Product and Solutions
  2.5.4 Dana-Farber Cancer Institute Recent Developments and Future Plans
2.6 Mesoblast
  2.6.1 Mesoblast Details
  2.6.2 Mesoblast Major Business
  2.6.3 Mesoblast Graft vs. Host Disease (GvHD) Stem Cell Therapy Product and Solutions
  2.6.4 Mesoblast Recent Developments and Future Plans
2.7 Takeda
  2.7.1 Takeda Details
  2.7.2 Takeda Major Business
  2.7.3 Takeda Graft vs. Host Disease (GvHD) Stem Cell Therapy Product and Solutions
  2.7.4 Takeda Recent Developments and Future Plans

3 MARKET COMPETITION, BY PLAYERS

3.1 Global Graft vs. Host Disease (GvHD) Stem Cell Therapy Revenue and Share by Players (2026 & 2032)
3.2 Graft vs. Host Disease (GvHD) Stem Cell Therapy Players Head Office, Products and Services Provided
3.3 Graft vs. Host Disease (GvHD) Stem Cell Therapy Mergers & Acquisitions
3.4 Graft vs. Host Disease (GvHD) Stem Cell Therapy New Entrants and Expansion Plans

4 GLOBAL GRAFT VS. HOST DISEASE (GVHD) STEM CELL THERAPY FORECAST BY REGION

4.1 Global Graft vs. Host Disease (GvHD) Stem Cell Therapy Market Size by Region: 2026 VS 2032
4.2 Global Graft vs. Host Disease (GvHD) Stem Cell Therapy Market Size by Region, (2026-2032)
4.3 North America
  4.3.1 Key Companies of Graft vs. Host Disease (GvHD) Stem Cell Therapy in North America
  4.3.2 Current Situation and Forecast of Graft vs. Host Disease (GvHD) Stem Cell Therapy in North America
  4.3.3 North America Graft vs. Host Disease (GvHD) Stem Cell Therapy Market Size and Prospect (2026-2032)
4.4 Europe
  4.4.1 Key Companies of Graft vs. Host Disease (GvHD) Stem Cell Therapy in Europe
  4.4.2 Current Situation and Forecast of Graft vs. Host Disease (GvHD) Stem Cell Therapy in Europe
  4.4.3 Europe Graft vs. Host Disease (GvHD) Stem Cell Therapy Market Size and Prospect (2026-2032)
4.5 Asia-Pacific
  4.5.1 Key Companies of Graft vs. Host Disease (GvHD) Stem Cell Therapy in Asia-Pacific
  4.5.2 Current Situation and Forecast of Graft vs. Host Disease (GvHD) Stem Cell Therapy in Asia-Pacific
  4.5.3 Asia-Pacific Graft vs. Host Disease (GvHD) Stem Cell Therapy Market Size and Prospect (2026-2032)
  4.5.4 China
  4.5.5 Japan
  4.5.6 South Korea
4.6 South America
  4.6.1 Key Companies of Graft vs. Host Disease (GvHD) Stem Cell Therapy in South America
  4.6.2 Current Situation and Forecast of Graft vs. Host Disease (GvHD) Stem Cell Therapy in South America
  4.6.3 South America Graft vs. Host Disease (GvHD) Stem Cell Therapy Market Size and Prospect (2026-2032)
4.7 Middle East & Africa
  4.7.1 Key Companies of Graft vs. Host Disease (GvHD) Stem Cell Therapy in Middle East & Africa
  4.7.2 Current Situation and Forecast of Graft vs. Host Disease (GvHD) Stem Cell Therapy in Middle East & Africa
  4.7.3 Middle East & Africa Graft vs. Host Disease (GvHD) Stem Cell Therapy Market Size and Prospect (2026-2032)

5 MARKET SIZE SEGMENT BY TYPE

5.1 Global Graft vs. Host Disease (GvHD) Stem Cell Therapy Market Forecast by Type (2026-2032)
5.2 Global Graft vs. Host Disease (GvHD) Stem Cell Therapy Market Share Forecast by Type (2026-2032)

6 MARKET SIZE SEGMENT BY APPLICATION

6.1 Global Graft vs. Host Disease (GvHD) Stem Cell Therapy Market Forecast by Application (2026-2032)
6.2 Global Graft vs. Host Disease (GvHD) Stem Cell Therapy Market Share Forecast by Application (2026-2032)

7 RESEARCH FINDINGS AND CONCLUSION

8 APPENDIX

8.1 Methodology
8.2 Research Process and Data Source
8.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Graft vs. Host Disease (GvHD) Stem Cell Therapy Revenue by Type, (USD Million) 2026 VS 2032
Table 2. Global Graft vs. Host Disease (GvHD) Stem Cell Therapy Revenue by Application, (USD Million), 2026 VS 2032
Table 3. Osiris Therapeutics Corporate Information, Head Office, and Major Competitors
Table 4. Osiris Therapeutics Major Business
Table 5. Osiris Therapeutics Graft vs. Host Disease (GvHD) Stem Cell Therapy Product and Solutions
Table 6. Belumosudil Corporate Information, Head Office, and Major Competitors
Table 7. Belumosudil Major Business
Table 8. Belumosudil Graft vs. Host Disease (GvHD) Stem Cell Therapy Product and Solutions
Table 9. UChicago Medicine Corporate Information, Head Office, and Major Competitors
Table 10. UChicago Medicine Major Business
Table 11. UChicago Medicine Graft vs. Host Disease (GvHD) Stem Cell Therapy Product and Solutions
Table 12. Leukemia & Lymphoma Society Corporate Information, Head Office, and Major Competitors
Table 13. Leukemia & Lymphoma Society Major Business
Table 14. Leukemia & Lymphoma Society Graft vs. Host Disease (GvHD) Stem Cell Therapy Product and Solutions
Table 15. Dana-Farber Cancer Institute Corporate Information, Head Office, and Major Competitors
Table 16. Dana-Farber Cancer Institute Major Business
Table 17. Dana-Farber Cancer Institute Graft vs. Host Disease (GvHD) Stem Cell Therapy Product and Solutions
Table 18. Mesoblast Corporate Information, Head Office, and Major Competitors
Table 19. Mesoblast Major Business
Table 20. Mesoblast Graft vs. Host Disease (GvHD) Stem Cell Therapy Product and Solutions
Table 21. Takeda Corporate Information, Head Office, and Major Competitors
Table 22. Takeda Major Business
Table 23. Takeda Graft vs. Host Disease (GvHD) Stem Cell Therapy Product and Solutions
Table 24. Global Graft vs. Host Disease (GvHD) Stem Cell Therapy Revenue (USD Million) by Players (2026 & 2032)
Table 25. Global Graft vs. Host Disease (GvHD) Stem Cell Therapy Revenue Share by Players (2026 & 2032)
Table 26. Graft vs. Host Disease (GvHD) Stem Cell Therapy Players Head Office, Products and Services Provided
Table 27. Graft vs. Host Disease (GvHD) Stem Cell Therapy Mergers & Acquisitions in the Past Five Years
Table 28. Graft vs. Host Disease (GvHD) Stem Cell Therapy New Entrants and Expansion Plans
Table 29. Global Market Graft vs. Host Disease (GvHD) Stem Cell Therapy Revenue (USD Million) Comparison by Region (2026 VS 2032)
Table 30. Global Graft vs. Host Disease (GvHD) Stem Cell Therapy Revenue Market Share by Region (2026-2032)
Table 31. Key Companies of Graft vs. Host Disease (GvHD) Stem Cell Therapy in North America
Table 32. Current Situation and Forecast of Graft vs. Host Disease (GvHD) Stem Cell Therapy in North America
Table 33. Key Companies of Graft vs. Host Disease (GvHD) Stem Cell Therapy in Europe
Table 34. Current Situation and Forecast of Graft vs. Host Disease (GvHD) Stem Cell Therapy in Europe
Table 35. Key Companies of Graft vs. Host Disease (GvHD) Stem Cell Therapy in Asia-Pacific
Table 36. Current Situation and Forecast of Graft vs. Host Disease (GvHD) Stem Cell Therapy in Asia-Pacific
Table 37. Key Companies of Graft vs. Host Disease (GvHD) Stem Cell Therapy in China
Table 38. Key Companies of Graft vs. Host Disease (GvHD) Stem Cell Therapy in Japan
Table 39. Key Companies of Graft vs. Host Disease (GvHD) Stem Cell Therapy in South Korea
Table 40. Key Companies of Graft vs. Host Disease (GvHD) Stem Cell Therapy in South America
Table 41. Current Situation and Forecast of Graft vs. Host Disease (GvHD) Stem Cell Therapy in South America
Table 42. Key Companies of Graft vs. Host Disease (GvHD) Stem Cell Therapy in Middle East & Africa
Table 43. Current Situation and Forecast of Graft vs. Host Disease (GvHD) Stem Cell Therapy in Middle East & Africa
Table 44. Global Graft vs. Host Disease (GvHD) Stem Cell Therapy Revenue Forecast by Type (2026-2032)
Table 45. Global Graft vs. Host Disease (GvHD) Stem Cell Therapy Revenue Forecast by Application (2026-2032)

List Of Figures

LIST OF FIGURES

Figure 1. Graft vs. Host Disease (GvHD) Stem Cell Therapy Picture
Figure 2. Global Graft vs. Host Disease (GvHD) Stem Cell Therapy Revenue Market Share by Type in 2032
Figure 3. Acute Graft-versus-host Disease
Figure 4. Chronic Graft-versus-host Disease
Figure 5. Graft vs. Host Disease (GvHD) Stem Cell Therapy Revenue Market Share by Application in 2032
Figure 6. Preclinical Picture
Figure 7. Clinical Phase 1,2 Picture
Figure 8. Global Graft vs. Host Disease (GvHD) Stem Cell Therapy Market Size, (USD Million): 2026 VS 2032
Figure 9. Global Graft vs. Host Disease (GvHD) Stem Cell Therapy Revenue and Forecast (2026-2032) & (USD Million)
Figure 10. Graft vs. Host Disease (GvHD) Stem Cell Therapy Market Drivers
Figure 11. Graft vs. Host Disease (GvHD) Stem Cell Therapy Market Restraints
Figure 12. Graft vs. Host Disease (GvHD) Stem Cell Therapy Market Trends
Figure 13. Osiris Therapeutics Recent Developments and Future Plans
Figure 14. Belumosudil Recent Developments and Future Plans
Figure 15. UChicago Medicine Recent Developments and Future Plans
Figure 16. Leukemia & Lymphoma Society Recent Developments and Future Plans
Figure 17. Dana-Farber Cancer Institute Recent Developments and Future Plans
Figure 18. Mesoblast Recent Developments and Future Plans
Figure 19. Takeda Recent Developments and Future Plans
Figure 20. Global Graft vs. Host Disease (GvHD) Stem Cell Therapy Revenue Market Share by Region (2026-2032)
Figure 21. Global Graft vs. Host Disease (GvHD) Stem Cell Therapy Revenue Market Share by Region in 2032
Figure 22. North America Graft vs. Host Disease (GvHD) Stem Cell Therapy Revenue (USD Million) and Growth Rate (2026-2032)
Figure 23. Europe Graft vs. Host Disease (GvHD) Stem Cell Therapy Revenue (USD Million) and Growth Rate (2026-2032)
Figure 24. Asia-Pacific Graft vs. Host Disease (GvHD) Stem Cell Therapy Revenue (USD Million) and Growth Rate (2026-2032)
Figure 25. South America Graft vs. Host Disease (GvHD) Stem Cell Therapy Revenue (USD Million) and Growth Rate (2026-2032)
Figure 26. Middle East & Africa Graft vs. Host Disease (GvHD) Stem Cell Therapy Revenue (USD Million) and Growth Rate (2026-2032)
Figure 27. Global Graft vs. Host Disease (GvHD) Stem Cell Therapy Market Share Forecast by Type (2026-2032)
Figure 28. Global Graft vs. Host Disease (GvHD) Stem Cell Therapy Market Share Forecast by Application (2026-2032)
Figure 29. Methodology
Figure 30. Research Process and Data Source